Molecular Mechanisms and Efficacy of Tislelizumab, a PD ‐1 Inhibitor Developed in China, in Non‐Small Cell Lung Cancer
Chemical Biology & Drug Design · 2026-02 · 107 (2)
DOI: 10.1111/cbdd.70252 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 28.01.2026. Verfasst von Yihao Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pain Management, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Foundation for Innovative Research Groups of the National Natural Science Foundation of China, the Sichuan Provincial Natural Science Foundation Project, the Key R&D Program for International Science and Technology Cooperation of the Gansu Provincial Science and Technology Program.
Abstract (Originalsprache)
Lung cancer remains the leading cause of cancer incidence and mortality worldwide, with non‐small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancer cases. Tislelizumab, a PD‐1 inhibitor developed in China, has shown promising efficacy as a monotherapy and in combination with chemotherapy. This study examines the molecular structure of tislelizumab and its interaction with PD‐1, along with its therapeutic effects and adverse reactions in NSCLC patients. Using GRAMM (Global Range Molecular Matching), protein–protein docking was conducted to analyze the binding affinity of tislelizumab with PD‐1. A comprehensive search in PubMed, Embase, Cochrane Library, and Web of Science identified eligible studies, including randomized controlled trials (RCTs) and single‐arm studies reporting survival outcomes, tumor responses, or adverse events. Tislelizumab significantly improved event‐free survival (RR = 1.40, 95% CI: 1.19–1.65) and median progression‐free survival (mPFS) by 1.77 months in RCTs, and reduced the risk of disease progression or death by 41% (HR = 0.59, 95% CI: 0.52–0.67). The overall survival risk was reduced by 35% (HR = 0.65, 95% CI: 0.59–0.73). The overall response rate (ORR) was higher in the tislelizumab group (RR = 1.86). In single‐arm studies, the 1‐year overall survival rate was 73.8%, with an ORR of 59.5%. AEs were generally manageable, with more frequent elevated ALT/AST, hypothyroidism, and rash, but fewer cases of anemia and neutropenia compared to chemotherapy. Tislelizumab significantly improves survival outcomes and tumor response rates in NSCLC patients, with an overall acceptable safety profile. For patients with suboptimal responses, dose adjustments or combination strategies may help improve efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pain Management, West China Hospital, Sichuan University, Chengdu, China.
- Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.
- Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
- Department of Biomedical Sciences, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Penang, Malaysia.
ORCID-Profile: Yihao Liu, Wenjun Meng, Lu Pan, Haoling Zhang, Qinqin He
Förderung
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China
- the Sichuan Provincial Natural Science Foundation Project
- the Key R&D Program for International Science and Technology Cooperation of the Gansu Provincial Science and Technology Program
- the Innovation Fund for Colleges and Universities of Gansu Province
- the Collaborative Innovation Center for Traditional Chinese Medicine Prevention and Control of Nutrition- and Environment-Related Diseases in Northwest China
- the Natural Science Project of the Gansu Provincial Department of Science and Technology
- National Natural Science Foundation of China
Zitieren
APA
Liu, Y., Meng, W., Pan, L., Zhang, H., & He, Q. (2026). Molecular Mechanisms and Efficacy of Tislelizumab, a PD ‐1 Inhibitor Developed in China, in Non‐Small Cell Lung Cancer. Chemical Biology & Drug Design, 107(2). https://doi.org/10.1111/cbdd.70252
Vancouver
Liu Y, Meng W, Pan L, Zhang H, He Q. Molecular Mechanisms and Efficacy of Tislelizumab, a PD ‐1 Inhibitor Developed in China, in Non‐Small Cell Lung Cancer. Chemical Biology & Drug Design. 2026;107(2). doi:10.1111/cbdd.70252
BibTeX
@article{Liu2026,
author = {Liu, Yihao and Meng, Wenjun and Pan, Lu and Zhang, Haoling and He, Qinqin},
title = {Molecular Mechanisms and Efficacy of Tislelizumab, a PD ‐1 Inhibitor Developed in China, in Non‐Small Cell Lung Cancer},
journal = {Chemical Biology & Drug Design},
year = {2026},
volume = {107},
number = {2},
doi = {10.1111/cbdd.70252}
}
EUVIMED